NewAmsterdam Pharma Company NV [NAMS] stock prices are up 2.28% to $16.60 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NAMS shares have gain 7.30% over the last week, with a monthly amount glided 3.11%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Scotiabank started tracking the stock with Sector Outperform rating on March 14, 2024, and set its price target to $35. On January 18, 2024, Guggenheim initiated with a Buy rating and assigned a price target of $30 on the stock. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $37 on January 16, 2024. RBC Capital Mkts initiated its recommendation with a Outperform and recommended $25 as its price target on October 30, 2023.
The stock price of NewAmsterdam Pharma Company NV [NAMS] has been fluctuating between $5.63 and $26.35 over the past year. Currently, Wall Street analysts expect the stock to reach $36.5 within the next 12 months. NewAmsterdam Pharma Company NV [NASDAQ: NAMS] shares were valued at $16.60 at the most recent close of the market. An investor can expect a potential return of 119.88% based on the average NAMS price forecast.
Analyzing the NAMS fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -27.95%, Pretax Profit Margin comes in at -30.72%, and Net Profit Margin reading is -30.73%. To continue investigating profitability, this company’s Return on Assets is posted at -0.51, Equity is -0.87 and Total Capital is -0.52. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.26 points at the first support level, and at 15.93 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.92, and for the 2nd resistance point, it is at 17.24.
Ratios To Look Out For
It’s worth pointing out that NewAmsterdam Pharma Company NV [NASDAQ:NAMS]’s Current Ratio is 9.83. As well, the Quick Ratio is 9.83, while the Cash Ratio is 9.51.
Transactions by insiders
Recent insider trading involved Audet Juliette Berangere, Chief Business Officer, that happened on Sep 26 ’24 when 1104.0 shares were purchased. Chief Executive Officer, Davidson Michael H. completed a deal on Aug 20 ’24 to buy 5000.0 shares. Meanwhile, Chief Executive Officer Davidson Michael H. bought 5000.0 shares on Jun 20 ’24.
